ALKS Alkermes plc - Ordinary Shares

54.57
-0.98  -1.76%
Previous Close 55.55
Open 55.03
Price To book 6.97
Market Cap 8.29B
Shares 151,970,000
Volume 860,925
Short Ratio 8.05
Av. Daily Volume 810,313

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 5 2015. sNDA filed for 2-month option August 8 2016. PDUFA date estimate June 8, 2017.
Aristada
Schizophrenia
Approved October 5 2015. sNDA filing due 2H 2016
Aristada
Schizophrenia
Phase 3 trial to be initiated 2017 with data and NDA filing due 2018. BPC estimate of data mid-2018.
ALKS 8700
Multiple sclerosis (MS)
Phase 3 initated September 2015. Data due 1H 2017.
ALKS 6428
Opioid dependence
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. NDA to be filed 2017.
ALKS 5461
Major depressive disorder
Pivotal trials initiated December 2015 and February 2016. Four week efficacy data due YE 2017. Six month weight data mid-2018.
ALKS 3831 - ENLIGHTEN-1 and ENLIGHTEN-2
Schizophrenia

Latest News

  1. Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
  2. ALKERMES PLC. Files SEC form 10-K, Annual Report
  3. Stress boom to boost drug sales?
  4. Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
  5. Alkermes Plc :ALKS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017
  6. Alkermes' Revenue Soars, Projects an Exciting Year Ahead
  7. Edited Transcript of ALKS earnings conference call or presentation 15-Feb-17 1:30pm GMT
  8. A solution to improve your patience as a trader
  9. Alkermes reports 4Q loss
  10. Alkermes reports 4Q loss
  11. ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  12. Q4 2016 Alkermes Plc Earnings Release - Before Market Open
  13. Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017
  14. Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017
  15. Why Sage Therapeutics Jumped Today
  16. Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results
  17. Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results
  18. Is Alkermes Poised for a Comeback in 2017?
  19. Naltrexone Showing More Potential in Drug Addiction Treatment Market
  20. Alkermes to expand manufacturing capacity, add new jobs